← All trials
NCT04490096
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Jul 28, 2020
- Last posted
- Jun 25, 2021
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of PennsylvaniaLead sponsor
- BiogenCollaborator
- University of PennsylvaniaOverall official - principal investigator
- University of MiamiCollaborator
- University of KansasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.